Peter Meeus to move from Biocon to become Advicenne CEO

7 January 2021

French biopharma Advicenne (Euronext: ADVIC) has named Peter Meeus its chief executive.

Mr Meeus will take up his position on February 15 and will replace André Ulmann, who has been serving as interim CEO and will assume the role of chief medical officer of the company.

David Horn Solomon, chairman of the board of directors, said: “Peter brings an extensive background as a leader in healthcare and has an impressive track record in execution and value creation within our industry. His significant commercial experience with companies in the European Union (EU) makes Peter an ideal candidate to lead Advicenne into its next stage of growth as we launch ADV7103 (Sibnayal) for the treatment of distal renal tubular acidosis (dRTA) in Europe.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK